Vericel Corporation (VCEL)
- Previous Close
43.86 - Open
43.67 - Bid 42.68 x 100
- Ask 42.91 x 100
- Day's Range
42.38 - 44.50 - 52 Week Range
29.24 - 53.05 - Volume
297,410 - Avg. Volume
467,527 - Market Cap (intraday)
2.064B - Beta (5Y Monthly) 1.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.07 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
53.90
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
vcel.comRecent News: VCEL
Performance Overview: VCEL
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VCEL
Valuation Measures
Market Cap
2.12B
Enterprise Value
2.10B
Trailing P/E
--
Forward P/E
294.12
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.57
Price/Book (mrq)
9.39
Enterprise Value/Revenue
10.63
Enterprise Value/EBITDA
733.40
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.61%
Return on Assets (ttm)
-1.29%
Return on Equity (ttm)
-1.52%
Revenue (ttm)
197.52M
Net Income Avi to Common (ttm)
-3.18M
Diluted EPS (ttm)
-0.07
Balance Sheet and Cash Flow
Total Cash (mrq)
109.56M
Total Debt/Equity (mrq)
38.96%
Levered Free Cash Flow (ttm)
-10.96M
Research Analysis: VCEL
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: VCEL
VCEL: Lowering target price to $50.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $50.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetVCEL: Lowering target price to $53.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $53.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetVCEL: Raising target price to $54.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $54.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetVCEL: Raising target price to $52.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $52.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingNeutralPrice Target